Responses
Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
501 AZD2796, a myeloid checkpoint inhibitor targeting LILRB2 that promotes pro-inflammatory responses by macrophages and enhances T cell anti-tumor activity
Compose a Response to This Article
Other responses
No responses have been published for this article.
